Increased risk of aortic aneurysm (AA) in relation to the severity of psoriasis: A national population-based matched-cohort study - 18/09/16
Abstract |
Background |
Inflammation of systemic and vascular tissues besides the skin in psoriasis is associated with cardiovascular morbidity and mortality.
Objective |
We sought to investigate whether or not patients with psoriasis have an increased risk of aortic aneurysm (AA).
Methods |
This population-based cohort study identified 34,301 patients with psoriasis in the Taiwan National Health Insurance Research Database during 2004 to 2006, who were matched for age and sex with 137,204 control subjects without psoriasis from the Taiwan Longitudinal Health Insurance Database 2000. Each individual was individually followed up for 5 years to identify those who subsequently developed AA.
Results |
After adjusting for medical history and medication use, patients with psoriasis were at increased overall risk of AA (adjusted hazard ratio [HR] 1.80; 95% confidence interval 1.25-2.61). The risk for AA increased with the severity of psoriasis. The adjusted HRs were higher for male than female patients (adjusted HR 1.84 vs 1.56), and for patients younger than 50 years versus older patients (adjusted HR 2.81 vs 1.64).
Limitations |
There is a lack of information regarding patients' Psoriasis Area and Severity Index score, daily tobacco use, or alcohol consumption.
Conclusion |
Patients with psoriasis are predisposed to developing AA: this risk increases with psoriasis severity and is independent of established cardiovascular risk factors.
Le texte complet de cet article est disponible en PDF.Key words : aortic aneurysm, cardiovascular diseases, comorbidities, inflammation, National Health Insurance Research Database, psoriasis
Abbreviations used : AA, HR, IL, NHI, NHIRD
Plan
| Drs Chiu and Lo contributed equally. |
|
| Supported by a grant from the Ministry of Science and Technology, Taiwan (formerly the National Science Council; grant numbers MOST104-2314-B-002 -117 -MY3) and was also funded by in part by National Taiwan University Hospital Hsin-Chu Branch (105-HCH064), which follows the guidelines on good publication practice; there were no other study sponsors. The study researchers and design, data collection, data analysis, interpretation of results, and writing of the manuscript are independent of funders. |
|
| Disclosure: All authors have completed the International Committee of Medical Journal Editors uniform disclosure form at coi_disclosure.pdf and declare that: Dr Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Pfizer Pharmaceuticals, Serono International SA (now Merck Serono International), UniPharma/Biogen Idec, Galderma, Celgene, Novartis Pharmaceuticals, and Janssen-Cilag Pharmaceutical, and received speaking fees from AbbVie. Dr Chiu received speaking fees from AbbVie, Janssen-Cilag Pharmaceutical, and Pfizer. Drs Lo, Huang, and Yi-Wen Tsai have no conflicts of interest to declare. This study is based in part on data from the National Health Insurance (NHI) Research Database, which is provided by the NHI Administration, Ministry of Health and Welfare, and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the NHI Administration, Ministry of Health and Welfare, or National Health Research Institutes. |
Vol 75 - N° 4
P. 747-754 - octobre 2016 Retour au numéro
Article précédent
- Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis
- April W. Armstrong, Keith A. Betts, Murali Sundaram, Darren Thomason, James E. Signorovitch
- Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study
- Inge E. Deckers, Ineke C. Janse, Hessel H. van der Zee, Tamar Nijsten, Jurr Boer, Barbara Horváth, Errol P. Prens
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?